BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

NCT01314105 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms
Peritoneal Neoplasms

Interventions

DRUG: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
DRUG: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
DRUG: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min

Sponsor

Boehringer Ingelheim